TURNING CLIENTS' IDEAS INTO MEANINGFUL INNOVATION

Syngene’s core capabilities include highly effective problem-solving and scientific innovation, allied to a clear commitment to safety, quality, and operating excellence. It takes an integrated approach to the disciplines of discovery, development and manufacturing of novel molecules to ensure a quality project delivery on time, every time — all with a single-minded commitment to turning clients’ ideas into meaningful innovation. Delivering timely, innovative, science, to reach clients and patients quickly and safely.

VISION

To be a world-class partner delivering innovative scientific solutions.

OUR BUSINESS

Syngene’s business is divided into four divisions — Discovery Services, Development Services, Manufacturing Services and Dedicated R&D Centres. Discovery Services conducts early-stage research, from target identification to delivery of drug candidates for further development. Development Services encompasses activities from pre-clinical to clinical trials including drug substance development, drug product development and associated services to demonstrate the safety, tolerability, and efficacy of the selected drug candidate. Manufacturing services for small and large molecules, including cGMP compliant facilities, for clinical supplies and registration batches as well as commercial volumes.

Delivering services

With sustained focus on quality, affordable innovation and productivity

World class infrastructure

Audited successfully by US FDA, EMA, AAALAC, MHRA, ANVISA, PMDA and major life sciences partners

2 million sq. ft.*

R&D and manufacturing infrastructure

>4,700

Scientists

Areas of expertise

Works with clients in flexible, adaptable and customised partnership models for both small and large molecules

Over 400+

Active clients including global leaders in multiple sectors. Works with 8 of the world's top 10 pharmaceutical companies

Driving revenue growth

Maintaining profitability through sound cost discipline and a well-calibrated capital allocation strategy to build value over the long-term

Listed

In India on BSE and NSE in 2015

*As of March 31, 2021
### FACTS

- **Established**: 1993
- **Active clients**: >400
- **BD offices**: US, UK, Ireland, Germany
- **Infrastructure**: 2 million sq. ft. laboratory and manufacturing space
- **Patents held with clients**: 400+
- **Partnering models**: Fee for Services, Full Time Equivalent

### Services

- **Discovery, Development and Manufacturing**
- **Top 3 Markets**: US (74%), Europe (12%), Japan (5%)

### Values

- **Professionalism, Integrity, Excellence**
- **Operational footprints**: Bengaluru, Mangaluru, Hyderabad
- **Dedicated centres**: 4 (Amgen, Baxter, Bristol–Myers Squibb and Herbalife)

### Industries we serve

- Large and Mid-sized Biopharma, Animal Health, Agrochem, Consumer Goods, Chemicals/polymers

### Certification, Audits, Accreditations


### OUR REVENUES

<table>
<thead>
<tr>
<th>Year</th>
<th>Revenue (Rs Mn)</th>
<th>EBITDA (Rs Mn)</th>
<th>PAT (Rs Mn)</th>
<th>Net Fixed Assets (Rs Mn)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY17</td>
<td>12,716</td>
<td>4,783</td>
<td>2,873</td>
<td>22,537</td>
</tr>
<tr>
<td>FY18</td>
<td>14,849</td>
<td>5,266</td>
<td>3,054</td>
<td>11,858</td>
</tr>
<tr>
<td>FY19</td>
<td>19,007</td>
<td>6,119</td>
<td>3,316</td>
<td>16,505</td>
</tr>
<tr>
<td>FY20</td>
<td>20,935</td>
<td>6,995</td>
<td>3,662</td>
<td>22,537</td>
</tr>
<tr>
<td>FY21</td>
<td>22,489</td>
<td>7,364</td>
<td>3,821</td>
<td>24,382</td>
</tr>
</tbody>
</table>
SUSTAINABILITY IN 2020
- 1.3 million man-hours without LTA
- 1000 KL/month reduction in water consumption
- 27,000 hours for safety training
- 1562 MT of solid waste recycled
- 14943 tonnes reduction in carbon dioxide

CSR AND COMMUNITY ENGAGEMENT

SYNGENE AT A GLANCE

PEOPLE
- 5000+ employees; >4700 Scientists
- 25% female employees
- 61,000 man-hours technical and behavioural training

OPERATIONAL EXCELLENCE
- White/Green belt certifications, Six Sigma, Kaizen and Lean Management

Research, Development and Manufacturing Services
Includes manufacturing of small and large molecules, including cGMP compliant facilities for clinical supplies and registration batches as well as commercial volumes. Dedicated R&D centres offer dedicated multi-disciplinary scientific teams, support personnel and ring-fenced infrastructure as per client specifications to support their R&D requirements.

Corporate Office
Syngene International Ltd, Biocon Park, SEZ
Bommasandra Industrial Area – Phase IV
Bommasandra-Jigani Link Road, Bangalore 560 099, India

Follow us at

Syngene processes COVID-19 samples free of charge during the pandemic.